Clinical Trial

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Study acronym: CASTLE-ZS-02
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-08-10
Trial Details
NCT Number NCT07070700
Lead Sponsor Fudan University
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Enrollment 56 participants
Start Date 2025-08-20
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-12